Literature DB >> 20123476

Outcomes beyond phenylalanine: an international perspective.

Francois Feillet1, Anita MacDonald, Danielle Hartung Perron, Barbara Burton.   

Abstract

Control of blood phenylalanine (Phe) levels throughout the life of a person diagnosed with phenylketonuria (PKU) is the biochemical management strategy necessary to provide the best potential for optimal outcome. Psychosocial support mechanisms comprise the other aspects of PKU management that are necessary to overcome the hurdles of living with this chronic disease and to adhere to the rigors of its management. Additional psychosocial support may be required, in light of increasing evidence that control of blood Phe levels in PKU can still lead to subtle but measurable cognitive function deficits as well as a predisposition to certain psychiatric symptoms and disorders. An all encompassing PKU management strategy that goes beyond simply treating blood Phe levels can empower and enable people born with PKU to achieve similar life goals as those born without PKU. This review looks at PKU management strategies that go beyond treating Phe levels, specifically (1) the roles psychologists play in managing PKU from infancy through adulthood and how they help PKU families and caregivers deal with the disease and the burden of its management; (2) understanding the challenges of transitioning into adulthood as an individual with PKU and addressing unmet needs in this population; (3) how non-traditional practices can be utilized in PKU. The objective is to emphasize that management of PKU goes well beyond addressing the biochemical nature of this disease in order to achieve optimal patient outcomes. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20123476     DOI: 10.1016/j.ymgme.2009.09.015

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  18 in total

1.  Successful Live Birth following Preimplantation Genetic Diagnosis for Phenylketonuria in Day 3 Embryos by Specific Mutation Analysis and Elective Single Embryo Transfer.

Authors:  Stuart Lavery; Dima Abdo; Mara Kotrotsou; Geoff Trew; Michalis Konstantinidis; Dagan Wells
Journal:  JIMD Rep       Date:  2012-03-31

2.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

3.  Transition of young adults with phenylketonuria from pediatric to adult care.

Authors:  Ulrike Mütze; Annika Roth; Johannes F W Weigel; Skadi Beblo; Christoph G Baerwald; Peter Bührdel; Wieland Kiess
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

4.  Efficacy of a New Low-Protein Multimedia Diet App for PKU.

Authors:  Sharon Evans; Catherine Ashmore; Anne Daly; Perninder Dhadwar; Atif Syed; Olivia Lecocq; Richard Jackson; Alex Pinto; Anita MacDonald
Journal:  Nutrients       Date:  2022-05-24       Impact factor: 6.706

5.  Processing speed and executive abilities in children with phenylketonuria.

Authors:  Alicia L Janos; Dorothy K Grange; Robert D Steiner; Desirée A White
Journal:  Neuropsychology       Date:  2012-08-06       Impact factor: 3.295

6.  Dietary habits and metabolic control in adolescents and young adults with phenylketonuria: self-imposed protein restriction may be harmful.

Authors:  A M Das; K Goedecke; U Meyer; N Kanzelmeyer; S Koch; S Illsinger; T Lücke; H Hartmann; K Lange; H Lanfermann; L Hoy; X-Q Ding
Journal:  JIMD Rep       Date:  2013-11-13

7.  Table of Phenylalanine Content of Foods: Comparative Analysis of Data Compiled in Food Composition Tables.

Authors:  Ana Claudia Marquim F Araújo; Wilma M C Araújo; Ursula M Lanfer Marquez; Rita Akutsu; Eduardo Y Nakano
Journal:  JIMD Rep       Date:  2016-10-08

8.  Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy.

Authors:  Nicola Longo; Komudi Siriwardena; Annette Feigenbaum; David Dimmock; Barbara K Burton; Sylvia Stockler; Susan Waisbren; William Lang; Elaina Jurecki; Charlie Zhang; Suyash Prasad
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

Review 9.  Suggested guidelines for the diagnosis and management of urea cycle disorders.

Authors:  Johannes Häberle; Nathalie Boddaert; Alberto Burlina; Anupam Chakrapani; Marjorie Dixon; Martina Huemer; Daniela Karall; Diego Martinelli; Pablo Sanjurjo Crespo; René Santer; Aude Servais; Vassili Valayannopoulos; Martin Lindner; Vicente Rubio; Carlo Dionisi-Vici
Journal:  Orphanet J Rare Dis       Date:  2012-05-29       Impact factor: 4.123

Review 10.  Achieving the "triple aim" for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework.

Authors:  Beth K Potter; Pranesh Chakraborty; Jonathan B Kronick; Kumanan Wilson; Doug Coyle; Annette Feigenbaum; Michael T Geraghty; Maria D Karaceper; Julian Little; Aizeddin Mhanni; John J Mitchell; Komudi Siriwardena; Brenda J Wilson; Ania Syrowatka
Journal:  Genet Med       Date:  2012-12-06       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.